196 related articles for article (PubMed ID: 31835235)
1. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
Pasquier D; Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Petit A; Mouret-Reynier MA; Goncalves A; Dalenc F; Deluche E; Fresnel JS; Augereau P; Ferrero JM; Geffrelot J; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Mouttet-Audouard R; Bachelot T; Courtinard C
Eur J Cancer; 2020 Jan; 125():22-30. PubMed ID: 31835235
[TBL] [Abstract][Full Text] [Related]
2. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
3. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
4. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database.
Carausu M; Carton M; Cabel L; Patsouris A; Levy C; Verret B; Pasquier D; Debled M; Gonçalves A; Desmoulins I; Lecouillard I; Bachelot T; Ferrero JM; Eymard JC; Mouret-Reynier MA; Chevrot M; De Maio E; Uwer L; Frenel JS; Leheurteur M; Petit T; Darlix A; Bozec L
Ther Adv Med Oncol; 2022; 14():17588359221077082. PubMed ID: 35237352
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
7. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
[TBL] [Abstract][Full Text] [Related]
8. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
[TBL] [Abstract][Full Text] [Related]
9. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
10. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.
Gougis P; Carton M; Tchokothe C; Campone M; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Bachelot T; Hennequin A; Perrin C; Gonçalves A; Uwer L; Eymard JC; Petit T; Mouret-Reynier MA; Chamorey E; Simon G; Saghatchian M; Cailliot C; Le Tourneau C
Breast; 2020 Feb; 49():17-24. PubMed ID: 31675683
[TBL] [Abstract][Full Text] [Related]
11. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
13. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
14. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.
Masci G; Agostinetto E; Giordano L; Bottai G; Torrisi R; Losurdo A; De Sanctis R; Navarria P; Scorsetti M; Zuradelli M; de Rose F; Bello L; Santoro A
Future Oncol; 2020 Mar; 16(7):269-279. PubMed ID: 32043375
[No Abstract] [Full Text] [Related]
16. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).
Pérol D; Robain M; Arveux P; Mathoulin-Pélissier S; Chamorey E; Asselain B; Berchery D; Gourgou S; Breton M; Delaine-Clisant S; Mons M; Diéras V; Carton M; Guizard AV; Laborde L; Laurent C; Loeb A; Mouret-Reynier MA; Parent D; Perrocheau G; Campion L; Velten M; Cailliot C; Ezzalfani M; Simon G
BMJ Open; 2019 Feb; 9(2):e023568. PubMed ID: 30796119
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
18. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Heudel P; Delaloge S; Parent D; Madranges N; Levy C; Dalenc F; Brain E; Uwer L; D'Hondt V; Augereau P; Mailliez A; Perrin C; Frenel JS; Sablin MP; Mouret-Reynier MA; Vermeulin T; Eymard JC; Petit T; Ferrero JM; Ilie S; Goncalves A; Chenuc G; Robain M; Simon G; Perol D
Anticancer Res; 2020 Jul; 40(7):3905-3913. PubMed ID: 32620631
[TBL] [Abstract][Full Text] [Related]
19. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
[TBL] [Abstract][Full Text] [Related]
20. Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms.
Cacho-Díaz B; Salmerón-Moreno K; Alvarez-Alvarez A; Mendoza-Olivas LG; Alvarado-Miranda A; Villarreal-Garza C; Reynoso-Noverón N; Chávez-MacGregor M; Meneses-García AA
Cancer; 2020 Aug; 126(15):3456-3463. PubMed ID: 32453447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
